Gemmer Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Gemmer Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-780	Closed	-$66K	–	1329
2020 Q1	$66K	Sell	780 -20	-3%	-$1.72K	0.02%	146
2019 Q4	$68K	Sell	800 -2	-0.2%	-$151	0.02%	164
2019 Q3	$54K	Buy	802 +2	+0.3%	+$154	0.01%	184
2019 Q2	$69K	Hold	800	–	–	0.02%	154
2019 Q1	$71K	Hold	800	–	–	0.02%	150
2018 Q4	$68K	Hold	800	–	–	0.02%	142
2018 Q3	$78K	Sell	800 -200	-20%	-$20K	0.02%	136
2018 Q2	$94K	Sell	1,000 -700	-41%	-$61.3K	0.03%	120
2018 Q1	$138K	Sell	1,700 -500	-23%	-$42.9K	0.05%	100
2017 Q4	$196K	Hold	2,200	–	–	0.07%	82
2017 Q3	$205K	Hold	2,200	–	–	0.08%	80
2017 Q2	$200K	Sell	2,200 -550	-20%	-$50K	0.08%	82
2017 Q1	$241K	Sell	2,750 -1,600	-37%	-$142K	0.11%	69
2016 Q4	$360K	Buy	4,350 +3,600	+480%	+$310K	0.18%	51
2016 Q3	$69K	Buy	+750	New	+$70.6K	0.04%	129

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Gemmer Asset Management's BMRN Position: Q2 2020 in Review

Gemmer Asset Management sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2020, closing a stake of 780 shares — an estimated $66K sold.

Gemmer Asset Management first reported a position in BMRN in Q3 2016 and held it in 15 quarters. The position peaked at $360K in Q4 2016. 527 funds tracked by Wall St. Rank hold BMRN as of Q2 2020.

Gemmer Asset Management reported no remaining BioMarin Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
Gemmer Asset Management sold 780 BioMarin Pharmaceuticals shares in Q2 2020, an estimated $66K.
Gemmer Asset Management first reported a position in BioMarin Pharmaceuticals in Q3 2016 and held it in 15 quarters.
Gemmer Asset Management's BioMarin Pharmaceuticals position peaked at $360K in Q4 2016.
527 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2020.

Based on Gemmer Asset Management's 13F filing for Q2 2020, filed 31 Jul 2020.